S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.11 (-2.92%)
AAPL   121.94 (-2.54%)
MSFT   227.14 (-2.88%)
FB   255.41 (-1.39%)
GOOGL   2,013.00 (-2.49%)
TSLA   652.03 (-5.01%)
AMZN   3,004.00 (-2.93%)
NVDA   512.28 (-4.47%)
BABA   235.72 (+0.55%)
CGC   33.26 (-5.65%)
GE   13.46 (+3.70%)
MU   89.25 (-2.02%)
NIO   41.85 (-3.33%)
AMD   80.84 (-3.91%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.47 (-5.08%)
DIS   192.00 (-1.00%)
BA   228.80 (+2.54%)
NFLX   521.70 (-4.77%)
PFE   34.37 (+2.57%)
S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.11 (-2.92%)
AAPL   121.94 (-2.54%)
MSFT   227.14 (-2.88%)
FB   255.41 (-1.39%)
GOOGL   2,013.00 (-2.49%)
TSLA   652.03 (-5.01%)
AMZN   3,004.00 (-2.93%)
NVDA   512.28 (-4.47%)
BABA   235.72 (+0.55%)
CGC   33.26 (-5.65%)
GE   13.46 (+3.70%)
MU   89.25 (-2.02%)
NIO   41.85 (-3.33%)
AMD   80.84 (-3.91%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.47 (-5.08%)
DIS   192.00 (-1.00%)
BA   228.80 (+2.54%)
NFLX   521.70 (-4.77%)
PFE   34.37 (+2.57%)
S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.11 (-2.92%)
AAPL   121.94 (-2.54%)
MSFT   227.14 (-2.88%)
FB   255.41 (-1.39%)
GOOGL   2,013.00 (-2.49%)
TSLA   652.03 (-5.01%)
AMZN   3,004.00 (-2.93%)
NVDA   512.28 (-4.47%)
BABA   235.72 (+0.55%)
CGC   33.26 (-5.65%)
GE   13.46 (+3.70%)
MU   89.25 (-2.02%)
NIO   41.85 (-3.33%)
AMD   80.84 (-3.91%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.47 (-5.08%)
DIS   192.00 (-1.00%)
BA   228.80 (+2.54%)
NFLX   521.70 (-4.77%)
PFE   34.37 (+2.57%)
S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.11 (-2.92%)
AAPL   121.94 (-2.54%)
MSFT   227.14 (-2.88%)
FB   255.41 (-1.39%)
GOOGL   2,013.00 (-2.49%)
TSLA   652.03 (-5.01%)
AMZN   3,004.00 (-2.93%)
NVDA   512.28 (-4.47%)
BABA   235.72 (+0.55%)
CGC   33.26 (-5.65%)
GE   13.46 (+3.70%)
MU   89.25 (-2.02%)
NIO   41.85 (-3.33%)
AMD   80.84 (-3.91%)
T   28.72 (+1.77%)
F   12.17 (-3.03%)
ACB   10.47 (-5.08%)
DIS   192.00 (-1.00%)
BA   228.80 (+2.54%)
NFLX   521.70 (-4.77%)
PFE   34.37 (+2.57%)
Log in
NASDAQ:SNDL

Sundial Growers Competitors

$1.29
-0.09 (-6.52 %)
(As of 03/3/2021 04:15 PM ET)
Add
Compare
Today's Range
$1.26
Now: $1.29
$1.42
50-Day Range
$0.56
MA: $1.20
$2.95
52-Week Range
$0.14
Now: $1.29
$3.96
Volume4.35 million shs
Average Volume672.64 million shs
Market Capitalization$2.01 billion
P/E RatioN/A
Dividend YieldN/A
Beta7.01

Competitors

Sundial Growers (NASDAQ:SNDL) Vs. APHA, TLRY, CRON, ACB, USNA, and HEXO

Should you be buying SNDL stock or one of its competitors? Companies in the industry of "medicinals & botanicals" are considered alternatives and competitors to Sundial Growers, including Aphria (APHA), Tilray (TLRY), Cronos Group (CRON), Aurora Cannabis (ACB), USANA Health Sciences (USNA), and HEXO (HEXO).

Aphria (NASDAQ:APHA) and Sundial Growers (NASDAQ:SNDL) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.

Institutional & Insider Ownership

10.3% of Aphria shares are held by institutional investors. Comparatively, 3.3% of Sundial Growers shares are held by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Aphria and Sundial Growers' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aphria-36.10%-2.30%-1.66%
Sundial Growers-415.89%-187.67%-72.67%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Aphria and Sundial Growers, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aphria03602.67
Sundial Growers12001.67

Aphria currently has a consensus price target of $17.7857, suggesting a potential downside of 5.34%. Sundial Growers has a consensus price target of $1.00, suggesting a potential downside of 24.81%. Given Aphria's stronger consensus rating and higher probable upside, equities research analysts clearly believe Aphria is more favorable than Sundial Growers.

Valuation & Earnings

This table compares Aphria and Sundial Growers' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aphria$405.96 million14.54$-63,210,000.00($0.06)-310.50
Sundial Growers$75.86 million27.27$-204,570,000.00($3.17)-0.42

Aphria has higher revenue and earnings than Sundial Growers. Aphria is trading at a lower price-to-earnings ratio than Sundial Growers, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Aphria has a beta of 2.67, suggesting that its share price is 167% more volatile than the S&P 500. Comparatively, Sundial Growers has a beta of 7.01, suggesting that its share price is 601% more volatile than the S&P 500.

Summary

Aphria beats Sundial Growers on 10 of the 13 factors compared between the two stocks.

Sundial Growers (NASDAQ:SNDL) and Tilray (NASDAQ:TLRY) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Analyst Ratings

This is a summary of current recommendations and price targets for Sundial Growers and Tilray, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sundial Growers12001.67
Tilray212001.86

Sundial Growers currently has a consensus price target of $1.00, indicating a potential downside of 24.81%. Tilray has a consensus price target of $18.0770, indicating a potential downside of 30.04%. Given Sundial Growers' higher probable upside, analysts plainly believe Sundial Growers is more favorable than Tilray.

Insider and Institutional Ownership

3.3% of Sundial Growers shares are owned by institutional investors. Comparatively, 12.6% of Tilray shares are owned by institutional investors. 16.8% of Tilray shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Sundial Growers has a beta of 7.01, indicating that its stock price is 601% more volatile than the S&P 500. Comparatively, Tilray has a beta of 3.12, indicating that its stock price is 212% more volatile than the S&P 500.

Valuation and Earnings

This table compares Sundial Growers and Tilray's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sundial Growers$75.86 million27.27$-204,570,000.00($3.17)-0.42
Tilray$166.98 million26.58$-321,170,000.00($1.69)-15.29

Sundial Growers has higher earnings, but lower revenue than Tilray. Tilray is trading at a lower price-to-earnings ratio than Sundial Growers, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sundial Growers and Tilray's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sundial Growers-415.89%-187.67%-72.67%
Tilray-242.60%-92.70%-20.70%

Summary

Tilray beats Sundial Growers on 8 of the 13 factors compared between the two stocks.

Cronos Group (NASDAQ:CRON) and Sundial Growers (NASDAQ:SNDL) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, earnings and profitability.

Institutional & Insider Ownership

11.8% of Cronos Group shares are held by institutional investors. Comparatively, 3.3% of Sundial Growers shares are held by institutional investors. 7.9% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Cronos Group has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500. Comparatively, Sundial Growers has a beta of 7.01, suggesting that its stock price is 601% more volatile than the S&P 500.

Profitability

This table compares Cronos Group and Sundial Growers' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cronos Group266.31%-1.61%-1.41%
Sundial Growers-415.89%-187.67%-72.67%

Analyst Recommendations

This is a breakdown of recent ratings for Cronos Group and Sundial Growers, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cronos Group25202.00
Sundial Growers12001.67

Cronos Group currently has a consensus target price of $8.8333, indicating a potential downside of 16.35%. Sundial Growers has a consensus target price of $1.00, indicating a potential downside of 24.81%. Given Cronos Group's stronger consensus rating and higher possible upside, research analysts plainly believe Cronos Group is more favorable than Sundial Growers.

Valuation & Earnings

This table compares Cronos Group and Sundial Growers' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos Group$25.64 million147.67$1.17 billion$0.6715.69
Sundial Growers$75.86 million27.27$-204,570,000.00($3.17)-0.42

Cronos Group has higher earnings, but lower revenue than Sundial Growers. Sundial Growers is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Summary

Cronos Group beats Sundial Growers on 12 of the 14 factors compared between the two stocks.

Aurora Cannabis (NYSE:ACB) and Sundial Growers (NASDAQ:SNDL) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Aurora Cannabis and Sundial Growers, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aurora Cannabis69001.60
Sundial Growers12001.67

Aurora Cannabis currently has a consensus target price of $11.2445, indicating a potential upside of 5.48%. Sundial Growers has a consensus target price of $1.00, indicating a potential downside of 24.81%. Given Aurora Cannabis' higher probable upside, equities analysts clearly believe Aurora Cannabis is more favorable than Sundial Growers.

Profitability

This table compares Aurora Cannabis and Sundial Growers' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aurora Cannabis-1,238.94%-16.32%-13.12%
Sundial Growers-415.89%-187.67%-72.67%

Volatility and Risk

Aurora Cannabis has a beta of 3.44, indicating that its share price is 244% more volatile than the S&P 500. Comparatively, Sundial Growers has a beta of 7.01, indicating that its share price is 601% more volatile than the S&P 500.

Earnings and Valuation

This table compares Aurora Cannabis and Sundial Growers' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Cannabis$207.89 million10.08$-2,468,190,000.00($2.86)-3.71
Sundial Growers$75.86 million27.27$-204,570,000.00($3.17)-0.42

Sundial Growers has lower revenue, but higher earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Sundial Growers, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

11.9% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 3.3% of Sundial Growers shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Aurora Cannabis beats Sundial Growers on 7 of the 12 factors compared between the two stocks.

Sundial Growers (NASDAQ:SNDL) and USANA Health Sciences (NYSE:USNA) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.

Institutional & Insider Ownership

3.3% of Sundial Growers shares are held by institutional investors. Comparatively, 54.1% of USANA Health Sciences shares are held by institutional investors. 45.4% of USANA Health Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Sundial Growers and USANA Health Sciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sundial Growers$75.86 million27.27$-204,570,000.00($3.17)-0.42
USANA Health Sciences$1.06 billion1.98$100.53 million$4.4122.67

USANA Health Sciences has higher revenue and earnings than Sundial Growers. Sundial Growers is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Sundial Growers has a beta of 7.01, indicating that its share price is 601% more volatile than the S&P 500. Comparatively, USANA Health Sciences has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Sundial Growers and USANA Health Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sundial Growers12001.67
USANA Health Sciences00203.00

Sundial Growers currently has a consensus target price of $1.00, suggesting a potential downside of 24.81%. USANA Health Sciences has a consensus target price of $126.00, suggesting a potential upside of 26.01%. Given USANA Health Sciences' stronger consensus rating and higher possible upside, analysts clearly believe USANA Health Sciences is more favorable than Sundial Growers.

Profitability

This table compares Sundial Growers and USANA Health Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sundial Growers-415.89%-187.67%-72.67%
USANA Health Sciences10.57%32.91%22.26%

Summary

USANA Health Sciences beats Sundial Growers on 12 of the 14 factors compared between the two stocks.

HEXO (NYSE:HEXO) and Sundial Growers (NASDAQ:SNDL) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Volatility & Risk

HEXO has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Sundial Growers has a beta of 7.01, meaning that its share price is 601% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for HEXO and Sundial Growers, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
HEXO67301.81
Sundial Growers12001.67

HEXO currently has a consensus price target of $1.9455, suggesting a potential downside of 72.68%. Sundial Growers has a consensus price target of $1.00, suggesting a potential downside of 24.81%. Given Sundial Growers' higher possible upside, analysts plainly believe Sundial Growers is more favorable than HEXO.

Earnings and Valuation

This table compares HEXO and Sundial Growers' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HEXO$60.46 million14.29$-406,370,000.00($0.96)-7.36
Sundial Growers$75.86 million27.27$-204,570,000.00($3.17)-0.42

Sundial Growers has higher revenue and earnings than HEXO. HEXO is trading at a lower price-to-earnings ratio than Sundial Growers, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

35.3% of HEXO shares are held by institutional investors. Comparatively, 3.3% of Sundial Growers shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares HEXO and Sundial Growers' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HEXO-517.61%-13.15%-10.35%
Sundial Growers-415.89%-187.67%-72.67%

Summary

Sundial Growers beats HEXO on 7 of the 13 factors compared between the two stocks.

Ad Legacy Research
Buffett Dumps $800M Of Apple, Buys This Instead!
Warren Buffett recently dumped $800 million of Apple stock… He’s now moved $3.8 BILLION in a tiny niche of the tech sector billionaires are flocking to…

Sundial Growers Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Aphria logo
APHA
Aphria
1.3$18.63-1.7%$6.00 billion$405.96 million-31.58Gap Down
Tilray logo
TLRY
Tilray
1.0$25.84-0.2%$4.45 billion$166.98 million-5.69Gap Down
Cronos Group logo
CRON
Cronos Group
0.7$10.51-1.0%$3.83 billion$25.64 million43.79Earnings Announcement
Analyst Report
Analyst Revision
Aurora Cannabis logo
ACB
Aurora Cannabis
1.1$10.62-3.9%$2.18 billion$207.89 million-0.43Decrease in Short Interest
Gap Down
USANA Health Sciences logo
USNA
USANA Health Sciences
2.0$99.99-0.9%$2.08 billion$1.06 billion18.52Insider Selling
HEXO logo
HEXO
HEXO
0.9$7.07-3.3%$891.79 million$60.46 million-1.45
ChromaDex logo
CDXC
ChromaDex
0.9$11.62-6.8%$766.79 million$46.29 million-30.58Upcoming Earnings
MediWound logo
MDWD
MediWound
1.4$5.49-6.4%$140.00 million$31.79 million-13.72Earnings Announcement
Analyst Report
Decrease in Short Interest
Analyst Revision
Gap Down
Natural Alternatives International logo
NAII
Natural Alternatives International
0.4$15.07-0.8%$96.58 million$118.88 million188.40Increase in Short Interest
News Coverage
HAPP
Happiness Biotech Group
0.6$2.02-1.0%$51.80 million$65.06 million0.00
HUGE
FSD Pharma
0.3$1.97-5.1%$39.67 million$190,000.00-0.44Increase in Short Interest
MTEX
Mannatech
1.1$18.37-0.0%$38.36 million$157.73 million5.65News Coverage
CYAN
Cyanotech
0.6$3.82-0.8%$23.29 million$31.90 million38.20Decrease in Short Interest
This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.